Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MiniAp4-trastuzumab conjugate
- Development stage
- Preclinical
- Lead developer
- Gate2Brain
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
01
Overview
MiniAp4-trastuzumab conjugate (also known as Tz-MiniAp4) is a preclinical-stage antibody-shuttle conjugate (ASC) developed by Gate2Brain. It consists of the anti-HER2 monoclonal antibody trastuzumab site-specifically conjugated to four molecules of MiniAp-4, a protease-resistant blood-brain barrier (BBB) shuttle peptide. The MiniAp-4 peptide facilitates transcytosis across the BBB and blood-tumor barrier (BTB), enabling the large antibody molecule to access the central nervous system. Once across, trastuzumab binds to human epidermal growth factor receptor 2 (HER2) on tumor cells, inhibiting downstream signaling and preventing the development and growth of HER2-positive brain metastases. This therapeutic candidate is being investigated for the prevention and treatment of HER2-related brain metastasis.
- Other names
- MiniAp-4 ASCMiniAp4 ASCMiniAp 4 ASCMiniAp-4-trastuzumab conjugateMiniAp4-trastuzumab conjugateMiniAp 4-trastuzumab conjugateMiniAp4-antibody conjugateMiniAp-4-antibody conjugateMiniAp 4-antibody conjugateTz-MiniAp4Tz-MiniAp-4Tz-MiniAp 4
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on MiniAp4-trastuzumab conjugate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MiniAp4-trastuzumab conjugate.